Publications by authors named "A Boureille"
Background: Anti-TNF are usually maintained during pregnancy in patients with inflammatory bowel disease (IBD) but safety is still a concern for them.
Aims: To provide data on management of anti-TNF agents during pregnancy, safety of live vaccines (BCG-MMR-rotavirus) and breastfeeding in newborns and dedicated information delivered to IBD women.
Methods: We performed an observational study in 25 centers from 2016 to 2018.
Somatic mutations in the () promoter regions are frequent events in urothelial cancer (UC) and their detection in urine (supernatant cell-free DNA or DNA from exfoliated cells) could serve as putative non-invasive biomarkers for UC detection and monitoring. However, detecting these tumor-borne mutations in urine requires highly sensitive methods, capable of measuring low-level mutations. In this study, we developed sensitive droplet digital PCR (ddPCR) assays for detecting promoter mutations (C228T, C228A, CC242-243TT, and C250T).
View Article and Find Full Text PDFArticle Synopsis
- Capsule endoscopy (CE) is the leading technique for examining the small bowel, but analyzing the extensive video data, averaging 50,000 frames, can take 30 to 60 minutes per video.
- The CAD-CAP database was created from third-generation SB-CE videos collected from 12 French endoscopy centers to aid in developing computer-assisted diagnosis tools for this labor-intensive reading process.
- The database contains 4,174 SB-CE videos, with 1,480 showing pathological findings, leading to the extraction and categorization of over 5,000 frames of various lesions and 20,000 normal frames for training and validation of automated detection tools.
Detection of molecular alterations in lung cancer bone metastasis (LCBM) is particularly difficult when decalcification procedure is needed. The Idylla™ real-time (RT)-PCR is compared to the routine method used in our laboratory, which combines next generation and Sanger sequencing, for the detection of mutations in LCBM. LCBM subjected to EDTA or formic acid decalcification were analysed for mutational status using two methods: first, the Ion Torrent Ampliseq next generation sequencing (NGS) assay +/- Sanger sequencing was used prospectively; then, the fully-automated, RT-PCR based molecular testing system Idylla™ Mutation Test was applied retrospectively.
View Article and Find Full Text PDFBackground & Aims: Few data are available on the effects of tumor necrosis factor (TNF) antagonist therapy for patients with internal fistulizing Crohn's disease (CD) and there is debate regarding the risk of abscess. We aimed to assess the long-term efficacy and safety of anti-TNF therapy for patients with internal fistulas.
Methods: We performed a retrospective study of data collected from the Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives trial, from January 1, 2000, through December 31, 2017.